Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.83 |
| ▸ | DRD2 | P14416 | 4/20 | 0.83 |
| ▸ | HTR2A | P28223 | 4/20 | 0.83 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.75 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.75 |
| ▸ | DRD1 | P21728 | 1/20 | 0.75 |
| ▸ | DRD4 | P21917 | 1/20 | 0.75 |
| ▸ | ACHE | P22303 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.75 |
| ▸ | CCKBR | P32239 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | HRH1 | P35367 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1544871 | 0.99 | HTR1A (0.82) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL9005353 | 0.93 | HTR1A (0.81) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL8788175 | 0.91 | HTR1A (0.77) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| Hydrochloric Acid SCHEMBL7775068 | 0.90 | HTR1A (0.76) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL9101152 | 0.90 | HTR1A (0.68) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL8346535 | 0.90 | HTR1A (0.77) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL1545700 | 0.89 | HTR1A (0.80) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL1544998 | 0.89 | HTR1A (0.74) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL1546355 | 0.89 | HTR1A (0.76) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL27523253 | 0.88 | HTR1A (0.73) | HTR1ADRD2HTR2AHRH3ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39198-E1 | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics | AVENTIS PHARMACEUTICALS INC. (US) | 2006-07-18 | — | — | US | claimed |
| US-5364866-A | Side effect reduction | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1994-11-15 | — | — | US | claimed |
| EP-0612318-A1 | HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-08-31 | — | — | EP | claimed |
| EP-0542136-A1 | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-05-19 | — | — | EP | claimed |
| WO-1993009102-A1 | HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1993-05-13 | — | — | WO | claimed |
| US-20240016791-A1 | ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | VANDA PHARMACEUTICALS INC. | 2024-01-18 | — | — | US | disclosed |
| US-20210015809-A1 | ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | VANDA PHARMACEUTICALS INC. | 2021-01-21 | — | — | US | disclosed |
| US-10874659-B2 | Iloperidone metabolite for use in the treatment of psychiatric disorders | VANDA PHARMACEUTICALS INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-5561128-A | ANALGESICS; ANTIPSYCHOTIC AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1996-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016791-A1 | ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CYP2C8, RGS8, UGT1A8 | HTR1A 49/4885DRD2 36/4885HTR2A 27/4885 |
| US-20210015809-A1 | ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CYP2C8, RGS8, UGT1A8 | HTR1A 49/4885DRD2 36/4885HTR2A 27/4885 |
| US-10874659-B2 | Iloperidone metabolite for use in the treatment of psychiatric disorders | CYP2C8, RGS8, UGT1A8 | HTR1A 49/4885DRD2 36/4885HTR2A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.